# YESight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yesight

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.yesight.com
- Latest round: Series A (Oct 22, 2025)
- Investors on record: 4

## About

Established in 2020 and based in Suzhou, China, YESight is a medical device company focusing on ophthalmic medical devices, integrating R&D, manufacturing, sales and AI big data research. The company is headquartered in Suzhou, China, and also has a research institute in Japan, while signing a framework agreement with TOP3 Opticians Group Inc. in Japan for sales of some products. As for the team, the company's team has engineering R&D strength and the ability to iterate on ophthalmic medical device devices.

In January 2021, YESight closed angel funding from new investor Guoqian Venture Capital. In October 2025, YESight raised an undisclosed amount of series A+ funding from new investor Yuanhe Puhua Suzhou Management and another investor.

YESight specializes in the development and manufacturing of advanced ophthalmic medical devices, with a primary focus on its flagship product, the Yetsea ultra-widefield scanning laser ophthalmoscope (SLO). This device provides comprehensive retinal imaging to allow eye care professionals to diagnose and monitor various ocular diseases with enhanced precision. The Yetsea SLO utilizes advanced confocal laser scanning techniques for high-resolution images of the retina, promoting early detection of conditions such as diabetic retinopathy and glaucoma. The company markets its products primarily to hospitals, specialized ophthalmology clinics, and research institutions across established markets, including North America, Europe, and select regions in Asia. YESight generates revenue through direct sales of its ophthalmic devices to healthcare providers and institutions, emphasizing B2B transactions.

The series A+ funding will be mainly used by the company to accelerate the commercialization of its core products, Scanning Laser Ophthalmoscope (SLO) in domestic and international markets, as well as the research and development of a variety of innovative ophthalmic optical equipment.

## Funding rounds

- Series A, Oct 22, 2025 — Yuanhe Puhua Suzhou Management
- Series A, Jun 12, 2023 — Delian Capital, Insight Capital
- Angel, Jan 11, 2021 — Guoqian Venture Capital

## Investors

- Guoqian Venture Capital (https://capitalatlas.ai/funds/guoqian-venture-capital) — Angel
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Insight Capital — Series A
- Yuanhe Puhua Suzhou Management (https://capitalatlas.ai/funds/yuanhe-puhua-suzhou-management) — Series A